Prestige Consumer Healthcare PBH International OTC Healthcare — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Prestige Consumer Healthcare in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Prestige Consumer Healthcare’s 10-K, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prestige Consumer Healthcare's international otc healthcare — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Prestige Consumer Healthcare's international OTC healthcare — cost of sales?
- Prestige Consumer Healthcare (PBH) reported international OTC healthcare — cost of sales of $22.15M in Q1 2026.
- How has Prestige Consumer Healthcare's international OTC healthcare — cost of sales changed year-over-year?
- Prestige Consumer Healthcare's international OTC healthcare — cost of sales increased by 16.3% year-over-year, from $19.05M to $22.15M.
- What is the long-term trend for Prestige Consumer Healthcare's international OTC healthcare — cost of sales?
- Over 4 years (2022 to 2026), Prestige Consumer Healthcare's international OTC healthcare — cost of sales has grown at a 14.4% compound annual growth rate (CAGR), from $47M to $80.43M.
- What does international OTC healthcare — cost of sales mean?
- This represents the direct costs attributable to the production and distribution of over-the-counter healthcare products within the international segment. It includes raw materials, manufacturing labor, and logistics expenses required to bring products to market. Monitoring this helps assess the production efficiency and cost structure of international operations.